CLEVELAND, March 19, 2020 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that Enloe Medical Center – an
independent, nonprofit hospital in Chico, California– has entered into a master
agreement for the purchase of a MRIdian MRI-guided radiation
therapy system. Upon installation, Enloe Medical Center will
become the first community hospital in Northern California to offer MRIdian
treatments.
Enloe Medical Center is affiliated with the UCSF Helen Diller
Family Comprehensive Cancer Center, an affiliation aimed at
enhancing care and improving access to medical experts and
high-quality, specialty treatment for residents throughout the
region. Enloe's program integrates all facets of cancer care in a
patient-centered environment using leading-edge technologies.
MRIdian fits Enloe Medical Center's patient-centered approach by
helping clinicians more precisely deliver radiation to tumors while
avoiding surrounding tissues and organs. MRIdian allows for
continuous imaging during the delivery of radiation therapy,
enabling clinicians to directly view and track the tumor during
treatment.
"As Enloe Medical Center looks towards the future of cancer
services for the communities we serve, we wanted to align ourselves
with a technology platform and a company that will partner with our
organizational mission," said Brady
Haynes, Chief Operations Officer at Enloe Medical Center.
"After a twelve-month process, we have decided that company is
ViewRay and the technology selection is the MRIdian Linac
System."
"The purchase of a MRIdian system for Enloe Medical Center
supports the hospital's mission to improve quality of life through
patient-centered care," said Paul
Ziegler, Senior Vice President of Global Sales and Marketing
at ViewRay. "We are pleased that they are taking this exciting step
forward in bringing the benefits of MRI-guided radiation therapy to
their patients."
Currently 34 MRIdian systems are installed at hospitals around
the world, where they are being used to treat a wide variety of
solid tumors and are the focus of numerous ongoing research
efforts. MRIdian has been the subject of hundreds of peer-reviewed
publications, scientific meeting abstracts and presentations. More
than 8,000 patients have been treated with MRIdian. For a list of
treatment centers, please visit:
https://viewray.com/mridian-locator.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures,
and markets the MRIdian® radiation therapy system. MRIdian is built
upon a proprietary high-definition MR imaging system designed from
the ground up to address the unique challenges and clinical
workflow for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purposely
built to deliver high-precision radiation without unnecessary beam
distortion, and consequently, help to mitigate skin toxicity and
other safety concerns that may otherwise arise when high magnetic
fields interact with radiation beams.
About Enloe Medical Center
Enloe Medical Center is a local, nonprofit health care
organization. For more information, please call (530) 332-7300 or
visit www.enloe.org. Enloe Medical Center is located at 1531
Esplanade Chico, Calif. 95926.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Private Securities Litigation
Reform Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, the rate of new orders,
upgrades and installations, ViewRay's financial guidance for the
full year 2020 and ViewRay's conference calls to discuss its fourth
quarter 2019 and year to date results. Actual results could differ
from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the ability
to commercialize MRIdian Linac System, demand for ViewRay's
products, the ability to convert backlog into revenue, and the
timing of delivery of ViewRay's products, the timing, results and
other uncertainties associated with clinical trials, the ability to
raise the additional funding needed to continue to pursue ViewRay's
business and product development plans, the inherent uncertainties
associated with developing new products or technologies,
competition in the industry in which ViewRay operates and overall
market conditions. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to ViewRay's business in general, see ViewRay's current
and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2019 and its
2019 Quarterly Reports on Form 10-Q, as updated periodically with
the company's other filings with the SEC. These forward-looking
statements are made as of the date of this press release, and
ViewRay assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/enloe-medical-center-becomes-first-community-hospital-in-northern-california-to-purchase-a-mridian-mri-guided-radiation-therapy-system-301026622.html
SOURCE ViewRay, Inc.